Hospital
Mayo Clinic Health System-Southeast Minnesota Region
Mayo Clinic Health System-Southeast Minnesota Region was paid $37.49M by Medicaid between Jan 2018 and Dec 2024, across 216 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 37% of everything it billed.
33Billing provider infoMAYO CLINIC HEALTH SYSTEM-SOUTHEAST MINNESOTA REGION
ALBERT LEA, MN 56007
ALBERT LEA, MN 56007
33aNPI1346258100assigned 08/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.49M
24GClaims555,577
24DCodes billed216
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#5 of 36
Median peer was paid$11.46M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MEKALA, PRAVEEN controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 75,639 | $1.76M | |
| 2019 | 81,209 | $5.21M | |
| 2020 | 70,110 | $4.31M | |
| 2021 | 89,204 | $5.91M | |
| 2022 | 100,358 | $7.27M | |
| 2023 | 87,711 | $7.34M | |
| 2024incomplete | 51,346 | $5.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 37% | 197,133 | 179,563 | $13.73M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 22,110 | 19,076 | $8.10M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 28,266 | 26,288 | $5.30M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 19,508 | 17,107 | $4.49M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.5% | 6,452 | 6,370 | $565K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 72,623 | 66,341 | $432K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 2,645 | 2,506 | $428K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 3,204 | 3,116 | $399K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 14,658 | 13,985 | $368K |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | <1% | 3,368 | 2,379 | $319K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15,432 | 14,912 | $293K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 2,643 | 2,607 | $231K |
204 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,746 | $196K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,711 | $177K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 765 | $172K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,282 | $126K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,766 | $117K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,067 | $107K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 988 | $104K |
| 11721 | <1% | 3,255 | $100K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 222 | $100K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 391 | $76K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,354 | $65K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 460 | $62K |
| 90461 | <1% | 5,100 | $61K | |
| 20553 | <1% | 343 | $61K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 977 | $60K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,241 | $58K |
| 80053 | Comprehensive metabolic panel | <1% | 13,457 | $58K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,273 | $55K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,273 | $55K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 175 | $49K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,150 | $49K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,065 | $44K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 346 | $40K |
| 90670 | <1% | 4,865 | $36K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 638 | $36K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 1,511 | $32K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 185 | $32K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 563 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,719 | $29K |
| 0002A | <1% | 770 | $28K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 284 | $28K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 481 | $28K |
| 83605 | <1% | 2,424 | $24K | |
| 87631 | <1% | 639 | $23K | |
| 90686 | <1% | 8,998 | $22K | |
| 96127 | <1% | 636 | $20K | |
| 73630 | <1% | 471 | $19K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 263 | $16K |
| 83655 | <1% | 741 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 379 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,525 | $15K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 167 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 201 | $14K |
| Q3014 | Telehealth originating site facility fee | <1% | 546 | $14K |
| 0001A | <1% | 391 | $14K | |
| 86780 | <1% | 997 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,215 | $12K |
| 80061 | Lipid panel | <1% | 987 | $12K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 473 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 779 | $11K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 553 | $11K |
| 99177 | <1% | 638 | $11K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 88 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 214 | $10K |
| 99223 | Prolong inpt eval add15 m | <1% | 82 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 189 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 381 | $9K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 459 | $9K |
| 81001 | <1% | 3,860 | $8K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 251 | $8K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 85 | $8K |
| 80050 | General health panel | <1% | 148 | $8K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,272 | $7K |
| 20611 | <1% | 43 | $6K | |
| 20610 | <1% | 30 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 52 | $6K |
| 96132 | <1% | 31 | $6K | |
| 0072A | <1% | 180 | $5K | |
| 85027 | <1% | 656 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 67 | $5K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 248 | $5K |
| 87340 | <1% | 260 | $4K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 73 | $4K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 58 | $4K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 212 | $4K |
| 92567 | <1% | 174 | $4K | |
| 86481 | <1% | 65 | $4K | |
| 84146 | <1% | 91 | $4K | |
| 83690 | <1% | 1,399 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 126 | $3K |
| 84484 | <1% | 887 | $3K | |
| 76801 | <1% | 25 | $3K | |
| 87660 | <1% | 389 | $3K | |
| 97161 | <1% | 34 | $3K | |
| 87510 | <1% | 389 | $3K | |
| 87480 | <1% | 389 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 579 | $2K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 12 | $2K |
| 31575 | <1% | 15 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $2K |
| 81003 | <1% | 571 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 37 | $2K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 66 | $2K |
| 0071A | <1% | 80 | $2K | |
| 90734 | <1% | 178 | $2K | |
| 87070 | <1% | 392 | $2K | |
| 17110 | <1% | 14 | $2K | |
| 90697 | <1% | 355 | $2K | |
| 86850 | <1% | 182 | $2K | |
| 92557 | <1% | 13 | $1K | |
| 92133 | <1% | 78 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 63 | $1K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $1K |
| 85610 | <1% | 1,252 | $1K | |
| 84702 | <1% | 125 | $1K | |
| 92134 | <1% | 57 | $1K | |
| 90716 | <1% | 75 | $1K | |
| 82805 | <1% | 115 | $1K | |
| 86787 | <1% | 85 | $1K | |
| 96136 | <1% | 31 | $1K | |
| 86769 | <1% | 36 | $1K | |
| 0012A | <1% | 28 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $888.74 |
| 0124A | <1% | 34 | $870.05 | |
| 90473 | <1% | 121 | $832.54 | |
| 0004A | <1% | 42 | $818.27 | |
| 71271 | <1% | 13 | $816.29 | |
| 90677 | <1% | 178 | $802.03 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 13 | $764.17 |
| 87653 | <1% | 15 | $713.32 | |
| 86762 | <1% | 72 | $669.30 | |
| 90480 | <1% | 26 | $642.39 | |
| 59025 | Fetal non-stress test | <1% | 20 | $632.71 |
| 0003A | <1% | 50 | $601.94 | |
| 98968 | <1% | 19 | $574.47 | |
| 81025 | <1% | 136 | $558.78 | |
| 86706 | <1% | 18 | $549.25 | |
| 87209 | <1% | 30 | $525.05 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 797 | $493.24 |
| 90656 | <1% | 256 | $450.92 | |
| 92015 | Determination of refractive state | <1% | 235 | $409.32 |
| 84439 | <1% | 25 | $403.92 | |
| 84460 | <1% | 54 | $357.22 | |
| 0052A | <1% | 14 | $337.56 | |
| 0013A | <1% | 16 | $333.70 | |
| 86140 | <1% | 256 | $309.55 | |
| 69210 | <1% | 13 | $300.34 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,139 | $277.18 |
| 90474 | <1% | 26 | $267.84 | |
| 87177 | <1% | 30 | $259.81 | |
| 90651 | <1% | 812 | $256.85 | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 25 | $251.10 |
| 85730 | <1% | 25 | $240.92 | |
| 84450 | <1% | 42 | $238.86 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $221.37 |
| 82950 | <1% | 42 | $203.28 | |
| G0008 | Administration of influenza virus vaccine | <1% | 14 | $196.40 |
| 86901 | <1% | 71 | $172.59 | |
| 86900 | <1% | 71 | $172.59 | |
| 95886 | <1% | 32 | $162.16 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,601 | $150.12 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 438 | $148.00 |
| 84478 | <1% | 27 | $147.25 | |
| 83735 | <1% | 198 | $132.81 | |
| 82248 | <1% | 305 | $122.78 | |
| 99173 | <1% | 237 | $118.49 | |
| 82607 | <1% | 15 | $111.37 | |
| 85018 | <1% | 26 | $109.72 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 262 | $96.45 |
| 73130 | <1% | 18 | $96.01 | |
| 82947 | <1% | 26 | $95.78 | |
| 73610 | <1% | 13 | $78.78 | |
| 96137 | <1% | 14 | $66.60 | |
| 99188 | <1% | 132 | $57.37 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,137 | $51.68 |
| 90672 | <1% | 122 | $31.08 | |
| 90744 | <1% | 1,109 | $29.74 | |
| A9270 | Non-covered item or service | <1% | 83 | $16.88 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 328 | $8.24 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 397 | $6.78 |
| 36416 | <1% | 122 | $3.26 | |
| 90619 | <1% | 31 | $2.94 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 165 | $2.63 |
| 90698 | <1% | 4,170 | $1.90 | |
| 90633 | <1% | 1,043 | $1.80 | |
| 90685 | <1% | 636 | $1.00 | |
| 90696 | <1% | 81 | $0.93 | |
| 90710 | <1% | 70 | $0.93 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 13 | $0.00 |
| 90680 | 0% | 2,095 | $0.00 | |
| V5008 | Hearing screening | 0% | 66 | $0.00 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 579 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 25 | $0.00 |
| 91307 | 0% | 314 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 28 | $0.00 |
| 92551 | 0% | 231 | $0.00 | |
| 91305 | 0% | 22 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 26 | $0.00 |
| 91301 | 0% | 25 | $0.00 | |
| 0065U | 0% | 12 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 12 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 30 | $0.00 |
| 86803 | 0% | 12 | $0.00 | |
| 90715 | 0% | 51 | $0.00 | |
| 91300 | 0% | 1,247 | $0.00 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 123 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 29 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 50 | $0.00 |
| 90691 | 0% | 15 | $0.00 | |
| 90707 | 0% | 36 | $0.00 | |
| 86682 | 0% | 19 | $0.00 | |
| 86765 | 0% | 12 | $0.00 | |
| 91312 | 0% | 19 | $0.00 | |
| 86735 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEKALA, PRAVEEN (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Mayo Clinic Health System-Southwest Minnesota Region | Mankato, MN | $28.51M |
| Mayo Clinic Health System-Southeast Minnesota Region | Albert Lea, MN | $21.76M |
| Mayo Clinic Health System-Southeast Minnesota Region | Owatonna, MN | $13.72M |
| Mayo Clinic Health System-Southeast Minnesota Region | Albert Lea, MN | $12.58M |
| Mayo Clinic Health System-Fairmont | Fairmont, MN | $9.04M |
| Mayo Clinic Health System-Southeast Minnesota Region | Red Wing, MN | $6.56M |
| Mayo Clinic Health System-Fairmont | Fairmont, MN | $4.71M |
| Mayo Clinic Health System-Southeast Minnesota Region | Red Wing, MN | $4.42M |
| Mayo Clinic Health System-Southwest Minnesota Region | Waseca, MN | $2.72M |
| Mayo Clinic Health System-Southwest Minnesota Region | New Prague, MN | $1.41M |
| Mayo Clinic Health System-Lake City | Lake City, MN | $653K |
| Mayo Clinic Health System-Southeast Minnesota Region | Cannon Falls, MN | $520K |
| Mayo Clinic Health System-Lake City | Lake City, MN | $265K |
| Mayo Clinic Health System-Lake City | Lake City, MN | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.